Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPO Year: 2021
Exchange: NASDAQ
Website: centurytx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | $6.00 | Buy | Rodman & Renshaw |
| 8/28/2023 | $28.00 → $5.00 | Overweight → Neutral | JP Morgan |
| 12/27/2022 | $19.00 | Buy | Chardan Capital Markets |
| 10/31/2022 | $15.00 | Buy | Guggenheim |
| 10/10/2022 | $28.00 | Buy | Canaccord Genuity |
| 5/23/2022 | $27.00 | Buy | H.C. Wainwright |
| 5/12/2022 | Mkt Perform | William Blair | |
| 11/19/2021 | $33.00 → $32.00 | Outperform | SVB Leerink |
| 7/13/2021 | $34.00 | Buy | BofA Securities |
| 7/13/2021 | $33.00 | Outperform | SVB Leerink |